Lilly and Insilico Medicine partnership logos

PARTNERSHIPS

7 Apr 2026

Insilico Does the Math, Lilly Writes the Check

Eli Lilly pays $115M upfront to license AI-designed oral drug candidates from Insilico Medicine in a deal worth up to $2.75B

Pills emerging from rolled US dollar

INVESTMENT

6 Apr 2026

Meet the Startup Trying to Out-Ozempic Ozempic

Ambrosia Biosciences closes an oversubscribed $100M Series B to launch US trials for a novel oral GLP-1 drug

Lilly scientists working with lab equipment in pharmaceutical research lab

PARTNERSHIPS

31 Mar 2026

The Shot Is So Last Year. Lilly Wants You to Pop a Pill

Eli Lilly and Nimbus Therapeutics team up in a deal worth up to $1.3B to develop a new oral obesity drug

Wegovy FlexTouch injection pens labeled 0.25 mg and 1 mg doses

REGULATORY

26 Mar 2026

Wegovy Turns Up the Dial and Takes Aim at Lilly

The FDA approved Novo Nordisk's 7.2 mg Wegovy HD in 54 days, with trial data showing 20.7% average weight loss

White tablets stacked on US dollar bill

INVESTMENT

23 Mar 2026

Oral Obesity Pill Push Draws $287M Bet

Corxel secures $287M to advance its oral GLP-1 pill CX11 through US and global trials as demand for needle-free options rises

Hand holding blue injectable pen device with cap removed

PARTNERSHIPS

17 Mar 2026

Why Novo Nordisk Is Putting $2 Billion Into a Pill

Novo Nordisk and Vivtex join forces in a $2.1B deal to develop next-generation oral biologics for obesity and diabetes

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.